ArticleJournal of the American Society of Nephrology : JASN2011
Risk for ESRD in type 1 diabetes remains high despite renoprotection.
Article in Journal of the American Society of Nephrology : JASN, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 97 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
97 citing papers in PubMed, 4 syntheses or guidelines pooled it, 185 citations in OpenAlex.
- Guideline
- Sex-specific association between type 1 diabetes and the risk of end-stage renal disease: a systematic review and meta-analysis.Endocrine · 2020Pooled it
- Type 1 diabetes, diabetic nephropathy, and pregnancy: a systematic review and meta-study.The review of diabetic studies : RDS · 2013Pooled it
- New susceptibility loci associated with kidney disease in type 1 diabetes.PLoS genetics · 2012Pooled it
- The effects of ursodeoxycholic acid on albuminuria in people with type 1 diabetes and diabetic kidney disease: a proof-of-concept study.Frontiers in endocrinology · 2026Trial
- The effect of zingiber officinale on prooxidant-antioxidant balance and glycemic control in diabetic patients with ESRD undergoing hemodialysis: a double-blind randomized control trial.BMC complementary medicine and therapies · 2023Trial
- Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes.The New England journal of medicine · 2020Trial
- Renal outcomes in patients with type 1 diabetes and macroalbuminuria.Journal of the American Society of Nephrology : JASN · 2014Trial
- Effects of sevelamer on HbA1c, inflammation, and advanced glycation end products in diabetic kidney disease.Clinical journal of the American Society of Nephrology : CJASN · 2012Trial
- MRPL12 regulates high glucose-induced ferroptosis in renal tubular epithelial cells via GPX4.BBA advances · 2026Article
- Time to diabetic nephropathy and its predictors among adult diabetic patients at public general and referral hospitals in South Wollo Zone, Northeast Ethiopia: A retrospective follow up study.SAGE open medicine · 2026Article
- Bioinformatics and systems biology to identify underlying common pathogenesis of diabetic kidney disease and stenosis of arteriovenous fistula.BMC nephrology · 2025Article
- Hybrid thiazolyl-benzylidene-phenol metal complexes as novel chemotherapeutic agents with anti-topoisomerase I activity in human breast carcinoma: synthesis,RSC advances · 2025Article
- Exploring the NRF2/HO-1 and NF-κB Pathways: Spirulina Nanoparticles as a Novel Approach to Combat Diabetic Nephropathy.ACS omega · 2024Article
- Clinical study of different prediction models in predicting diabetic nephropathy in patients with type 2 diabetes mellitus.World journal of diabetes · 2024Article
- Effect ofEvidence-based complementary and alternative medicine : eCAM · 2023Article
- Sirtuin Family and Diabetic Kidney Disease.Frontiers in endocrinology · 2022Review
- Cardiovascular autonomic neuropathy and the impact on progression of diabetic kidney disease in type 1 diabetes.BMJ open diabetes research & care · 2021Article
- Association of Coding Variants in Hydroxysteroid 17-beta Dehydrogenase 14 (Journal of the American Society of Nephrology : JASN · 2021Article
- Circulating proteins protect against renal decline and progression to end-stage renal disease in patients with diabetes.Science translational medicine · 2021Article
37 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
Abstract
Historically, patients with type 1 diabetes and macroalbuminuria had high competing risks: cardiovascular death or renal failure. Here, we assessed these risks in patients receiving therapies implemented during the last 30 years. Between 1991 and 2004, we enrolled 423 white patients with type 1 diabetes who developed macroalbuminuria (albumin excretion rate, ≥300 μg/min). With follow-up for 98% through 2008, ESRD developed in 172 patients (incidence rate, 5.8/100 person-years), and 29 died without ESRD (mortality rate, 1/100 person-years). The majority of these outcomes occurred between ages 36 and 52 years with durations of diabetes of 21 to 37 years. The 15-year cumulative risks were 52% for ESRD and 11% for pre-ESRD death. During the 15 years of follow-up, the use of renoprotective treatment increased from 56 to 82%, and BP and lipid levels improved significantly; however, the risks for both ESRD and pre-ESRD death did not change over the years analyzed. There were 70 post-ESRD deaths, and the mortality rate was very similar during the 1990s and the 2000s (11/100 person-years versus 12/100 person-years, respectively). Mortality was low in patients who received a pre-emptive kidney transplant (1/100 person-years), although these patients did not differ from dialyzed patients with regard to predialysis eGFR, sex, age at onset of ESRD, or duration of diabetes. In conclusion, despite the widespread adoption of renoprotective treatment, patients with type 1 diabetes and macroalbuminuria remain at high risk for ESRD, suggesting that more effective therapies are desperately needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.